Inclusion Body Myositis

Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)
Also Known As:
Myositis, Inclusion Body; Inclusion Body Myopathy, Sporadic; Inclusion Body Myositis, Sporadic; Myositis, Inclusion Body, Sporadic; Sporadic Inclusion Body Myositis; Inclusion Body Myositides; Myositides, Inclusion Body; Myopathy, Inclusion Body, Sporadic
Networked: 476 relevant articles (17 outcomes, 55 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Dermatomyositis (Dermatopolymyositis)
2. Polymyositis
3. Myositis (Idiopathic Inflammatory Myopathies)
4. Polyneuropathies (Polyneuropathy)
5. Inflammation


1. Engel, W King: 28 articles (06/2015 - 10/2002)
2. Askanas, Valerie: 28 articles (06/2015 - 10/2002)
3. Dalakas, Marinos C: 20 articles (09/2015 - 06/2003)
4. Nogalska, Anna: 16 articles (06/2015 - 03/2006)
5. Greenberg, Steven A: 13 articles (12/2014 - 10/2006)
6. Dalakas, M C: 12 articles (04/2011 - 01/2000)
7. Askanas, V: 12 articles (04/2007 - 04/2000)
8. Amato, Anthony A: 11 articles (08/2015 - 10/2003)
9. McFerrin, Janis: 10 articles (11/2007 - 02/2003)
10. Engel, W K: 10 articles (04/2007 - 04/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Inclusion Body Myositis:
1. Intravenous Immunoglobulins (IVIG)FDA Link
2. Immunoglobulins (Immunoglobulin)IBA
3. Immunoglobulin M (IgM)IBA
06/01/2004 - "In paraproteinemic IgM anti-MAG (myelin-associated glycoprotein) demyelinating polyneuropathies and inclusion body myositis (IBM), the benefit is variable, marginal, and not statistically significant. "
03/27/2012 - "Evidence is insufficient to support or refute use of IVIg in the treatment of immunoglobulin M paraprotein-associated neuropathy, inclusion body myositis, polymyositis, diabetic radiculoplexoneuropathy, or Miller Fisher syndrome, or in the routine treatment of postpolio syndrome or in children with GBS (Level U). "
05/01/1997 - "In other controlled or open-label trials and case reports, IVIg produced improvement in several patients with the Lambert-Eaton myasthenic syndrome and myasthenia gravis but had a variable, mild, or unsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinating polyneuropathy, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and the stiff-man syndrome. "
11/01/1999 - "The clinical efficacy of IVIg, based on controlled clinical trials conducted in patients with GBS, CIDP, multifocal motor neuropathy (MMN), DM, MG, LEMS, paraproteinemic IgM anti-myelin-associated glycoprotein (anti-MAG) demyelinating polyneuropathies, and inclusion body myositis is summarized and practical issues related to each disorder are addressed. "
04/01/2007 - "Recommendations for use of IVIG were made for 14 conditions, including acute disseminated encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, diabetic neuropathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen's encephalitis, and stiff person syndrome; IVIG was not recommended for 8 conditions including adrenoleukodystrophy, amyotropic lateral sclerosis, autism, critical illness polyneuropathy, inclusion body, myositis, intractable childhood epilepsy, paraproteinemic neuropathy (IgM variant), and POEMS syndrome. "
4. Adrenal Cortex Hormones (Corticosteroids)IBA
5. Myelin-Associated Glycoprotein (S-MAG)IBA
6. Monoclonal AntibodiesIBA
7. SteroidsIBA
8. alemtuzumab (Campath)FDA Link
9. Immunosuppressive Agents (Immunosuppressants)IBA
10. Amyloid (Amyloid Fibrils)IBA

Therapies and Procedures

1. Resistance Training
2. Mesenchymal Stem Cell Transplantation
3. Tendon Transfer
4. Activities of Daily Living (ADL)
5. Denervation